The health and economic burden of invasive pneumococcal diseases attributable to PCV21 or PCV20 serotypes among adults aged ≥18 years in Switzerland

Objectives Previous vaccination efforts have led to declining prevalence of serotypes targeted by vaccines, while those not covered have been increasing in prevalence. PCV21 is a vaccine targeting 21 serotypes, of which eight are not covered by any currently licensed vaccine. This study quantifies the burden of invasive pneumococcal disease (IPD) attributable to the serotypes included in PCV21 and PCV20 in adults aged ≥18 years in Switzerland. Methods A published Markov model examined the number of adult IPD cases, deaths and direct treatment costs incurred by serotypes covered by PCV21, in comparison to those covered by PCV20. Model outcomes were stratified by population age (18–49, 50–64, and over 65 years) and risk level (low risk, at risk, and high risk). Results Across all age and risk groups, PCV21 was responsible for a higher number of IPD cases, deaths, and direct treatment costs in Switzerland, relative to PCV20. The at-risk group had the highest IPD-related health and economic burden across all age groups. Conclusions PCV21 has the potential to prevent more of the health and economic burden associated with IPD in Switzerland, compared to PCV20. These results help to support policymaker decisions on adult vaccination in Switzerland.